Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome

Neurogastroenterology and Motility

Volumn 29, Issue 4, 2017, Pages

  Hustoft, T N ^a   Hausken, T ^a,b   Ystad, S O ^a,b   Valeur, J ^c   Brokstad, K ^a   Hatlebakk, J G ^a,b   Lied, G A ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c LOVISENBERG DIAKONALE HOSPITAL   (Norway)

Author keywords

FODMAPs; gut microbiota; irritable bowel syndrome; proinflammatory cytokines; short chain fatty acids

Indexed keywords

BUTYRIC ACID; CYTOKINE; DISACCHARIDE; INTERLEUKIN 6; INTERLEUKIN 8; MALTODEXTRIN; MONOSACCHARIDE; OLIGOSACCHARIDE; POLYOL; RNA 16S; SHORT CHAIN FATTY ACID; TUMOR NECROSIS FACTOR; VOLATILE FATTY ACID;

ACTINOBACTERIA; ADULT; ARTICLE; BACTERIAL COUNT; BIFIDOBACTERIUM; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FAECALIBACTERIUM PRAUSNITZII; FECES ANALYSIS; FECES MICROFLORA; FEMALE; FOOD COMPOSITION; HUMAN; IMMUNE RESPONSE; IRRITABLE COLON; LOW CARBOHYDRATE DIET; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM ASSESSMENT; SYMPTOMATOLOGY; ADMINISTRATION AND DOSAGE; ADOLESCENT; BLOOD; CARBOHYDRATE DIET; DIET THERAPY; DRUG EFFECTS; FECES; FERMENTED PRODUCT; MICROBIOLOGY; MIDDLE AGED; PHYSIOLOGY; TUMOR MICROENVIRONMENT; YOUNG ADULT;

ADOLESCENT; ADULT; CELLULAR MICROENVIRONMENT; CROSS-OVER STUDIES; CYTOKINES; DIETARY CARBOHYDRATES; DOUBLE-BLIND METHOD; FATTY ACIDS, VOLATILE; FECES; FEMALE; FERMENTED FOODS; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; OLIGOSACCHARIDES; YOUNG ADULT;

EID: 84991581649     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12969     Document Type: Article

References (42)

1. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313:949–958.
2. Soares RL. Irritable bowel syndrome: a clinical review. World J Gastroenterol. 2014;20:12144–12160.
3. Plavsic I, Hauser G, Tkalcic M, Pletikosic S, Salkic N. Diagnosis of irritable bowel syndrome: role of potential biomarkers. Gastroenterol Res Pract. 2015;2015:490183.
4. Marsh A, Eslick EM, Eslick GD. Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur J Nutr. 2016;55:897–906.
5. Barrett JS, Gibson PR. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals? Ther Adv Gastroenterol. 2012;5:261–268.
6. Ong DK, Mitchell SB, Barrett JS, et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol. 2010;25:1366–1373.
7. Gibson PR. Food intolerance in functional bowel disorders. J Gastroenterol Hepatol. 2011;26(Suppl 3):128–131.
8. Shepherd SJ, Lomer MC, Gibson PR. Short-chain carbohydrates and functional gastrointestinal disorders. Am J Gastroenterol. 2013;108:707–717.
9. Murray K, Wilkinson-Smith V, Hoad C, et al. Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI. Am J Gastroenterol. 2014;109:110–119.
10. El-Salhy M, Gundersen D. Diet in irritable bowel syndrome. Nutr J. 2015;14:36.
11. Bohn L, Storsrud S, Liljebo T, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015;149:1399–1407.e2.
12. Staudacher HM, Whelan K, Irving PM, Lomer MC. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet. 2011;24:487–495.
13. Miller LE. Study design considerations for irritable bowel syndrome clinical trials. Ann Gastroenterol. 2014;27:338–345.
14. Staudacher HM, Lomer MC, Anderson JL, et al. Fermentable carbohydrate restriction reduces luminal Bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr. 2012;142:1510–1518.
15. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11:395–402.
16. Shepherd SJ, Parker FC, Muir JG, Gibson PR. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol. 2008;6:765–771.
17. Coussement PA. Inulin and oligofructose: safe intakes and legal status. J Nutr. 1999;129(7 Suppl):1412S–1417S.
18. Marsh A, Eslick EM, Eslick GD. Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur J Nutr. 2015;55:897–906.
19. Casen C, Vebo HC, Sekelja M, et al. Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment Pharmacol Ther. 2015;42:71–83.
20. Zijlstra JB, Beukema J, Wolthers BG, Byrne BM, Groen A, Dankert J. Pretreatment methods prior to gas chromatographic analysis of volatile fatty acids from faecal samples. Clin Chim Acta. 1977;78:243–250.
21. Hoverstad T, Fausa O, Bjorneklett A, Bohmer T. Short-chain fatty acids in the normal human feces. Scand J Gastroenterol. 1984;19:375–381.
22. Gibson PR, Shepherd SJ. Evidence-based dietary management of functional gastrointestinal symptoms: the FODMAP approach. J Gastroenterol Hepatol. 2010;25:252–258.
23. Biesiekierski JR, Peters SL, Newnham ED, Rosella O, Muir JG, Gibson PR. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology. 2013;145:320–328.e1-3.
24. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59:325–332.
25. Lee BJ, Bak YT. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil. 2011;17:252–266.
26. McIntosh K, Reed DE, Schneider T, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. [published online March 14 2016] Gut. 2016. doi: 10.1136/gutjnl-2015-311339.
27. Roberfroid M, Gibson GR, Hoyles L, et al. Prebiotic effects: metabolic and health benefits. Br J Nutr. 2010;104(Suppl 2):S1–S63.
28. Staudacher HM, Whelan K. Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: probiotics, prebiotics and the low FODMAP diet. Proc Nutr Soc. 2016;75:306–318.
29. Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut. 2015;64:93–100.
30. Clarke ST, Green-Johnson JM, Brooks SP, et al. beta2-1 Fructan supplementation alters host immune responses in a manner consistent with increased exposure to microbial components: results from a double-blinded, randomised, cross-over study in healthy adults. Br J Nutr. 2016;115:1748–1759.
31. Bourdu S, Dapoigny M, Chapuy E, et al. Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. Gastroenterology. 2005;128:1996–2008.
32. Vanhoutvin SA, Troost FJ, Kilkens TO, et al. The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil. 2009;21:952–e76.
33. Kannampalli P, Shaker R, Sengupta JN. Colonic butyrate- algesic or analgesic? Neurogastroenterol Motil. 2011;23:975–979.
34. Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 2011;17:1519–1528.
35. Bashashati M, Rezaei N, Shafieyoun A, et al. Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil. 2014;26:1036–1048.
36. Bashashati M, Rezaei N, Andrews CN, et al. Cytokines and irritable bowel syndrome: where do we stand? Cytokine. 2012;57:201–209.
37. Rana SV, Sharma S, Sinha SK, Parsad KK, Malik A, Singh K. Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients. Trop Gastroenterol. 2012;33:251–256.
38. Seyedmirzaee S, Hayatbakhsh MM, Ahmadi B, et al. Serum immune biomarkers in irritable bowel syndrome. [published online February 2 2016] Clin Res Hepatol Gastroenterol. 2016. doi: 10.1016/j.clinre.2015.12.013.
39. Scully P, McKernan DP, Keohane J, et al. Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol. 2010;105:2235–2243.
40. Lied GA. Indication of immune activation in patients with perceived food hypersensitivity. Dig Dis Sci. 2014;59:259–266.
41. Dinan TG, Quigley EMM, Ahmed SMM, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology. 2006;130:304–311.
42. Hakansson A, Molin G. Gut microbiota and inflammation. Nutrients. 2011;3:637–682.